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The generation of antibody conjugates with a loading of two modules is desirable for a host of reasons.
Whilst certain antibody engineering approaches have been useful in the preparation of such constructs,
a reliable method based on a native antibody scaﬀold without the use of enzymes or harsh oxidative
conditions has hitherto not been achieved. The use of native antibodies has several advantages in terms
of cost, practicality, accessibility, time and overall eﬃciency. Herein we present a novel, reliable method
of furnishing antibody conjugates with a loading of two modules starting from a native antibody scaﬀold.Antibody conjugates play an important role in a variety of
applications, particularly in the eld of diagnostics and
therapeutics.1,2 In recent years, there has been signicant
interest in the area of antibody-drug conjugates (ADCs).2 ADCs
comprise antibodies covalently attached to highly potent drugs
using a linker conjugation technology.2 As therapeutics, they
conceptually combine the specicity of antibodies, i.e. enabling
discrimination between healthy and diseased tissue, with the
cell-killing ability of cytotoxic drugs. This powerful and exciting
class of targeted therapy has shown considerable promise
in the treatment of various cancers with two US Food and
Drug Administration approved ADCs currently on the market
(Adcetris™ and Kadcyla™)3,4 and approximately 40 currently
undergoing clinical evaluation.5 However, most of these ADCs
exist as heterogeneous mixtures, which can result in a narrow
therapeutic window and have major pharmacokinetic implica-
tions.2,6 In order for ADCs to achieve their full potential,
sophisticated site-specic conjugation technologies to connect
the drug to the antibody are increasingly being developed.2
Whilst a large number of reagents and strategies have been
developed to create these next generation ADCs, novel strategies
for site-specic conjugation continue to attract considerable
interest.2 This is especially important as it is coming to light that
specic requirements are essential for each particular ADC to
operate at its optimum.2 Whilst engineered antibodies have
worked well in meeting the demand for these tailor-made anti-
body conjugates, e.g. by using engineered cysteine residues,
unnatural amino acids, selenocysteine or enzymatic conjugation,7ge London, 20 Gordon Street, London,
c.uk; Tel: +44 (0)207 679 2077
ESI) available: 1H and 13C NMR spectra
GE gels and UV-vis analysis (where
: 10.1039/c6sc03655dthere is a requirement for methods that are based on native
antibody modication. This is to ensure that technologies to
make these “designer” ADCs are more accessible and cost-eﬀec-
tive; engineered approaches oen require signicant optimisa-
tion on each antibody scaﬀold they are applied, as well not being
accessible to a broad range of scientists.
It has recently come to light that in various tailor-made ADCs
one of the most desirable ratios of drugs to antibody is two. The
reason for this is that for certain hydrophobic drugs, e.g. pyr-
rolobenzodiazepines (PBDs), a loading of two is preferable as it
provides a good balance between eﬃcacy and pharmacokinetic
prole (higher payload loading tends to result in too rapid
clearance and lower loadings reduce eﬃcacy). This argument is
supported by the PBD-based ADCs that are currently in clinical
trials.2,8 Whilst this particular challenge has to some extent
been addressed by antibody engineering approaches, e.g. THI-
OMAbs for homogeneous DAR 2 conjugates, they are not readily
accessible and there are issues associated with the methodology
(e.g. potential for disulde scrambling and the ineﬃciency of
having to reduce, carefully re-oxidise and then conjugate).2
Thus, there is a need for a reliable method of constructing
antibody conjugates with a loading of two entities starting from
a native antibody construct. This is especially in the context of:
(i) the rapid progression in the development of further hydro-
phobic drugs being used and developed in the eld;8a,b,9 and
(ii) the major attempts on native antibodies (i.e. based on the
selective reduction of the Fab or hinge disuldes of an IgG1)10g,11
proving to lack broad applicability, as evidenced by the lack of
uptake in the eld, or having to employ harsh oxidation
conditions or enzymes under specic conditions.12 Herein we
detail the realisation of a reliable and reproducible strategy
to make antibody conjugates with a loading of two starting
from a native scaﬀold. It has signicant advantages in terms ofThis journal is © The Royal Society of Chemistry 2017
Fig. 1 Illustration detailing the typical approach to functional disulﬁde
re-bridging conjugates.
Edge Article Chemical Science
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
8 
N
ov
em
be
r 2
01
6.
 D
ow
nl
oa
de
d 
on
 1
4/
03
/2
01
7 
15
:5
7:
04
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinecost, practicality, accessibility, time and overall eﬃciency when
compared to existing methods.
Recently, we have shown dibromopyridazinediones
(diBrPDs) and dibromo/dithio-maleimides to be excellent
candidates for the functional re-bridging of inter-chain disul-
des in antibodies (Fig. 1). Moreover, the resulting bisthioether
conjugates have been shown to be stable in blood plasma-
mimicking conditions and retain activity plus selectivity in
vitro.10 The dibromomaleimide platform has also been shown to
be eﬀective in vivo by Jackson and co-workers.13 Whilst this
approach, as well as others,10,13,14 oﬀer advances in terms of
providing homogeneous DAR 4 conjugates starting from a non-
engineered antibody scaﬀold, there has as yet been no trans-
lation of the technologies to form controlled DAR 2 conjugates.
Nonetheless, we set out to explore if we could exploit the eﬃ-
cient functional re-bridging of disuldes with diBrPDs as
a conduit to realise the goal of controlled DAR 2 conjugate
formation starting from a native antibody scaﬀold. We envis-
aged that conjugation of two bis-dibromopyridazinediones
(containing a single functional modality) with an appropriate
linker length could “tie up” two pairs of the 4 disuldes on an
IgG1 to allow the formation of a conjugate with an overall
loading of two functional modules (see Fig. 2).
Our study began with the synthesis of an appropriate spaced
bis-dibromopyridazinedione, bis-diBrPD 1. As we were aiming
to react a pair of disuldes using bis-diBrPD 1 it was rational-
ised from the outset that the linker length would be key. If too
short, the bis-PD could not react with a pair of disuldes as it
could not span the appropriate length; too long and it wouldFig. 2 Illustration detailing a novel approach to achieving antibody
conjugate with a loading of two. Each pair of red and purple stars per
linker molecule are independently interchangeable, and other disulﬁde
pairs (e.g. Fab–Fab, hinge–hinge) may be functionally re-bridged.
This journal is © The Royal Society of Chemistry 2017increase the likelihood of undesirable intermolecular reac-
tion(s) by losing the high local concentration eﬀect – thus
resulting in ineﬃcient bridging of bis-diBrPD 1 across a pair of
disuldes. In an eﬀort to avoid these issues we designed a linker
based on the spacing of the disuldes on an IgG1 for which
a crystal structure has been obtained (16.7 A˚ ¼ maximum
linear distance).14,‡ To ensure exibility, and improve water
solubility of the bis-dibromopyridazinedione, a PEG spacer
was used to link together the PD bioconjugation sites. We
installed a single alkyne on the bis-PD scaﬀold so as to even-
tually allow a loading of two modules, through the use of click
chemistry, post-conjugation of bis-diBrPD 1 on a full antibody.
The click handle was also positioned by design to be close to
a PD-disulde bridging site to minimise exposure of the clicked
entity.
Compound 1 was synthesised by the route described in
Scheme 1; in view of the maximum linear distance between
inter-chain disuldes being 16.7 A˚ in the crystal structure of
the IgG1, 25 A˚ was anticipated to be a suitable separation
between the bridging sites when taking into account the reso-
lution of the measurement,15 the exibility of this region of the
antibody and the PEG chain not being structurally linear.
Initially, protected hydrazine 2 was formed via alkylation of
diboc-hydrazine (see ESI for further details†). This species was
then deprotected using TFA, and reacted with dibromomaleic
anhydride under reux in AcOH to aﬀord methyl-PD 3. Amide
coupling of this PD with a mono-boc protected bis-amine
resulted in the formation of PD linker reagent 4. Finally, this
species was deprotected and reacted with alkyne-PD 6 (prepared
in an analogous manner to methyl-PD 3) to aﬀord target
compound bis-diBrPD 1. Whilst the overall yield for theScheme 1 Synthesis of bis-diBrPD 1. Reagents and conditions: (i) TFA,
CH2Cl2, 21 C, 1 h; dibromomaleic anhydride, AcOH, reﬂux, 2 h; (ii)
tert-butyl (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)carba-
mate, CDI, DMF, 21 C, 12 h; (iii) TFA/DCM, 21 C, 30 min; (iv) HATU,
DIPEA, DMF, acid-alkyne PD 6 21 C, 16 h.
Chem. Sci., 2017, 8, 2056–2060 | 2057
Fig. 3 Illustration of bis-diBrPD her conjugate 7. Each pair of red and
purple stars per linker molecule are independently interchangeable,
and other disulﬁde pairs (e.g. Fab–Fab, hinge–hinge) may be func-
tionally re-bridged.
Fig. 4 Structure of conjugate 8 (each pair of green and purple stars
per linker molecule are independently interchangeable, and other
disulﬁde pairs (e.g. Fab–Fab, hinge–hinge) may be functionally re-
bridged); ELISA and SDS-PAGE gel (M: molecular weight marker; 1:
native Herceptin™; 2: conjugate 8) of conjugate 8 with native
Herceptin™ control.
Scheme 2 Synthesis of bis-diBrPD 9.
Chemical Science Edge Article
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View Article Onlinesynthesis was low (<5%) we do highlight that the chemistry is
straightforward to carry out and that none of the steps were
optimised as we were more interested in exploring the novel
chemical biology methodology.
Following the successful synthesis, the conjugation of 1 on
a full antibody was appraised on Herceptin™, a clinically
improved immunoglobulin used for the treatment of breast
cancer and the antibody component of FDA-approved ADC
Kadcyla™.4 On account of pyridazinediones having a signi-
cant extinction coeﬃcient at a distinct wavelength to other
entities in the corresponding antibody conjugate, UV-vis was
considered to be an appropriate method to analyse PD loading
on the antibody. To our delight, aer minimal optimisation,
reaction of Herceptin™ with bis-diBrPD 1 gave a pyr-
idazinedione-to-antibody ratio (PDAR) of 4.0 with complete
functional re-bridging conrmed by SDS-PAGE (including
under TCEP reducing conditions). This result supported our
hypothesis, as it suggested each bis-diBrPD had re-bridged two
disuldes; i.e. only such a result could have yielded the observed
SDS-PAGE prole and PDAR. Despite the challenges of using
mass spec for characterisation of antibody conjugates,16 espe-
cially for disulde modied conjugates,13 we obtained mass
spec data for conjugate 7 (see ESI for details†), which further
veried our observation; i.e. we observed two additions of bis-
diBrPD 1 to Herceptin™ (see representation in Fig. 3).
With conjugate 7 in hand, we next appraised what the
loading would be if we were to click on a uorophore-azide.
Owing to its favourable optical properties and our previous
experience with the azide,10i we chose to click on Alexa Fluor®
488 azide. To ensure that all available pendant alkynes on
conjugate 7 would be reacted, an excess of Alexa Fluor® 488
azide was used in the click reaction (20 eq.). Gratifyingly, these
conditions resulted in the formation of a conjugate where the
loading of the Alexa Fluor® 488 dye on the antibody conjugate
was 2.0. Furthermore, the result was highly reproducible with
the click reaction not aﬀecting PDAR or promoting antibody
degradation by SDS-PAGE. In addition to this, pre-click modi-
cation (i.e. carrying out the click reaction prior to bio-
conjugation) aﬀorded similar results (see ESI for details†).
It is also noteworthy that the nal conjugate retained
binding activity by ELISA (Fig. 4), even when compared to2058 | Chem. Sci., 2017, 8, 2056–2060classical diBrPD conjugation (see ESI for details†).10c,iMore than
this, the reactions were highly reproducible, with as many as
seven attempts showing PDARs in the range of 3.9–4.1 and Alexa
Fluor® 488 loadings in the range of 1.9–2.1. Finally, an ADC with
a DAR of 2.0, based on the “click” conjugation of an azide
functionalised doxorubicin10i to conjugate 7, was prepared in
a facile manner owing to the modular nature of the chemistry.
These results thus provide the rst examples of forming
a conjugate with a controlled loading of 2.0 on a native antibody
scaﬀold in a facile and reliable manner.
Not content with providing conjugates with a controlled
loading of two modules, we next turned our attention to the
synthesis of an antibody conjugate with a loading of four to
showcase the exibility of our strategy. This would also serve as
further proof of our disulde pair functional re-bridging
hypothesis as well as provide a novel conjugation strategy for
making antibody conjugates with a loading of four. To this end,This journal is © The Royal Society of Chemistry 2017
Fig. 5 Structure of conjugate 10 (other disulﬁde pairs (e.g. Fab–Fab,
hinge–hinge) may be functionally re-bridged); ELISA and SDS-PAGE
gel (M: molecular weight marker; 1: native Herceptin™; 2: conjugate
10) of conjugate 10 with native Herceptin™ control.
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View Article Onlinewe synthesised bis-diBrPD 9 in a similar manner to which bis-
diBrPD 1 was formed (see Scheme 2).
Pleasingly, application of the optimised conditions for
functional re-bridging, in the formation conjugate 7, to reagent
9 on Herceptin™ aﬀorded a conjugate with a PDAR 3.9 with all
disuldes of the antibody functionalised (Fig. 5, see ESI for
further details†). Moreover, reaction with an excess of Alexa
Fluor® 488 azide resulted in a uorophore loading of 3.9 (Fig. 5,
see ESI for details†). This, in combination with the SDS-PAGE
data, further veries the bridging mode of these rst-in-class
reagents, and ELISA data again showed binding to be unaf-
fected by the strategy. Moreover, it showcases how this novel
class of reagent can act as a branch point for the construction of
antibody conjugates with distinct and controlled module load-
ings of two and four.Conclusions
In conclusion, we have provided a rst-in-class strategy for
enabling the controlled, reproducible loading of two modules
onto a native antibody scaﬀold. This was enabled by the
successful synthesis and application of an entity, containing
one “click” handle, which functionally re-bridges two pairs of
disulde bonds on an IgG1. Subsequent reaction of the formed
conjugate with an azide-uorophore and azide-drug showed
that the controlled loading of two modules was feasible and
reproducible. The strategy, starting from the same branch
point, was also readily adapted for the formation of a conjugate
with a loading of four modules. Furthermore, all nal conju-
gates were shown to retain binding by ELISA and antibody-PD
conjugates have previously been shown to be biologically
functional and stable.10i–k We believe this simple yet elegantThis journal is © The Royal Society of Chemistry 2017approach to facilitate the loading of two modules starting from
a native antibody scaﬀold will nd application in multiple elds
where the controlled loading of lower than four entities is
desirable (e.g. antibody conjugates bearing highly hydrophobic
modules) and especially in laboratories where antibody engi-
neering techniques are not accessible, too expensive or not
practical.
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